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Automated database-guided expert-supervised orientation for
immunophenotypic diagnosis and classiﬁcation of acute
leukemia
L Lhermitte1,2,18, E Mejstrikova3,18, AJ van der Sluijs-Gelling4,5,18, GE Grigore6, L Sedek7, AE Bras8, G Gaipa9, E Sobral da Costa10,
M Novakova3, E Sonneveld4, C Buracchi8, T de Sá Bacelar10, JG te Marvelde8, A Trinquand1, V Asnaﬁ1, T Szczepanski11, S Matarraz12,
A Lopez12, B Vidriales13, J Bulsa11, O Hrusak3, T Kalina3, Q Lecrevisse12, M Martin Ayuso6, M Brüggemann14, J Verde6, P Fernandez15,
L Burgos16, B Paiva16, CE Pedreira17, JJM van Dongen5, A Orfao12,19 and VHJ van der Velden8,19 on behalf of the EuroFlow Consortium
Precise classiﬁcation of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation
tube (ALOT) to guide towards the relevant classiﬁcation panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-
ALL and/or acute myeloid leukemia (AML)) and ﬁnal diagnosis. Now we built a reference database with 656 typical AL samples (145
T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based
plots and automated classiﬁcation algorithms for direct comparison of single-cells from individual patients against the database,
another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical
T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this
automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the ﬁnal WHO-diagnosis was
already provided in493% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data
on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT
results and allows accurate selection of the relevant classiﬁcation panels, hence providing a solid basis for designing future WHO AL
classiﬁcations.
Leukemia (2018) 32, 874–881; doi:10.1038/leu.2017.313
INTRODUCTION
Acute leukemias (AL) are malignant expansions of aberrant
haematopoietic precursor cells arrested at very immature stages
of differentiation. Based on cytomorphologic, cytochemical and
ﬂowcytometric investigations, two main subgroups of AL, that is,
acute lymphoblastic leukemia (ALL) and acute myeloid leukemia
(AML) can be distinguished. Further subdivision of ALL fully relies
on immunophenotyping and allows identiﬁcation of T-cell acute
lymphoblastic leukemia (T-ALL) and B-cell precursor (BCP)-ALL.1,2
Appropriate diagnosis of these three main AL types is clinically
essential, since these groups (particularly ALL versus AML) differ
signiﬁcantly in treatment and prognosis.
Flowcytometric immunophenotyping is a key diagnostic tool to
identify the lineage of leukemic cells in AL patients. In a small
number of cases, appropriate lineage assessment can be tricky,
since the leukemic cells show no clear evidence of differentiation
along a single lineage or they express differentiation antigens
highly speciﬁc for more than one lineage.3 These cases account
for o5% of all acute leukemia (AL) cases and they are categorized
separately in the current WHO classiﬁcation as AL of ambiguous
lineage, including both acute undifferentiated leukemia (AUL) and
mixed phenotype AL (MPAL).3–5 For MPAL cases, the WHO
classiﬁcation has deﬁned the phenotypic criteria for cell lineage
assignment, that is, CD19 and Cytoplasmic (Cy)CD79a, CD10 and/
or CD22 for B-cells, CyCD3 or surface membrane (Sm)CD3 for
T-cells, and myeloperoxidase (CyMPO) or monocytic differentia-
tion markers (for example, CD14, CD64, CD11c) for myeloid
lineage.3,6
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Within EuroFlow, we have developed fully standardized
protocols and antibody panels for the diagnosis classiﬁcation
and monitoring of hematological malignancies.7–10 For AL, a single
eight-color tube (AL orientation tube, ALOT) was designed to
orientate towards the complementary panels for full characteriza-
tion of AL of different T, B and myeloid cell lineages. This tube
contained the cell-lineage deﬁning markers CyCD3, SmCD3, CD19,
CyCD79a and CyMPO, as well as the pan-leukocyte marker CD45,
the immature marker CD34 and CD7. Of note, CyCD79a was
preferred over CyCD22 because CD22 is not lineage speciﬁc as it is
also expressed at high levels in normal basophils, mast cells and
some dendritic cells.11 CD7 was selected because it is positive in
virtually all cases of T-ALL and in a subset of usually CyMPO-
negative AML;7 in BCP-ALL CD7 is occasionally observed in a
subset of MLL rearranged or Ph1pos BCP-ALLs.8 Despite ALOT is
standardized in terms of both reagent composition, sample
preparation, instrument set-up and data acquisition, ﬁnal inter-
pretation of the results still relies on local individual expertise and
relatively subjective/arbitrary criteria for identiﬁcation of leukemic
cells and deﬁnition of positivity for individual markers.
Here we report on the design, construction and validation of a
large ALOT database and the development of an automated
database-guided analytical algorithm to support subsequent
selection of the appropriate classiﬁcation panel(s) for the
diagnosis of AL patients. Standardized ALOT data7,8 collected in
the participating EuroFlow centers were combined in one large
database with hundreds of cases. This database served as a
pilaster for the design of a principal component analysis (PCA)-
guided algorithm for prospective classiﬁcation of individual tumor
cells per case, which was then validated in a series of over 780 AL
cases. Our results support the use of the ALOT database-guided
analytical tools to harmonize diagnostic strategies and to facilitate
fast, objective and reproducible diagnostics. In addition, these
tools may be used to improve selection of markers in a robust
manner for reﬁned future WHO classiﬁcation of AL.
MATERIALS AND METHODS
Acute leukemia patients
Patient characteristics are summarized in Table 1 and Supplementary Table
1. The institutional review board of each participating center approved this
study and informed consent for study participation was obtained from
each patient and/or his/her legal guardian.
Immunophenotyping
All samples were stained with the EuroFlow ALOT.8 Samples were stained
and acquired according to the EuroFlow Standard Operating Procedure
(SOP) and EuroFlow instrument settings.7 Appropriate instrument perfor-
mance and laboratory procedures were conﬁrmed by results obtained in
the EuroFlow quality assessment rounds12 and by additional analyses (see
Supplementary Information).
Study design
Data were collected in all participating EuroFlow centers. Resulting ﬂow
cytometry standard (.fcs) ﬁles were anonymized and analyzed using a
standard proﬁle in Inﬁnicyt software (Cytognos, Salamanca, Spain),
according to uniform gating instructions. Data (.fcs ﬁles and their
corresponding analyzed .cyt ﬁles) were uploaded on a secured server
(box-A), checked by a second expert (for correct acquisition, gating and
ﬂuorescence compensation), and if approved, subsequently transferred to
box-C, together with all required annotations (Supplementary Figure 1).
Atypical cases (for example, MPAL, AUL, blastic plasmacytoid dendritic cell
neoplasms) were not transferred to box-C but to box-X. Data in box-C from
all centers except two (Salamanca and Rotterdam) were used for building
the ALOT database. The resulting ALOT database was validated using the
remaining cases in box-C (Salamanca and Rotterdam cases) and atypical
cases from box-X, as well as prospectively acquired new AL samples
obtained in all participating centers for a total of 783 AL patients (47 T-ALL,
158 BCP-ALL, 522 AML, 55 MPAL, 1 AUL). Based on the (blinded) results,
several cases were requested to be reviewed locally, taking into account
not only the ALOT results, but also the information available from
subsequent classiﬁcation panels and genetics. Additional details are
provided in the Supplementary Methods.
ALOT database
For construction of the ALOT database, available .cyt ﬁles from 747 patients
were merged and grouped according to WHO-diagnosis in T-ALL, BCP-ALL
and AML groups. After performing quality checks (see Results section),
maximally 10 000 blast cells per case were exported from 656 cases and
included in the ALOT database. The ﬁnal ALOT database contained cases
belonging to three disease categories (groups): T, B and Myeloid AL. Each
group of cases was subsequently plotted in a balanced PCA plot,13 for
comparisons of (i) each case versus each of the three database groups, (ii)
each case versus all three groups at once, and/or (iii) individual cases
versus combinations of two database groups, the latter two comparisons
using pre-ﬁxed (balanced) PCA plots.
ALOT database-guided analysis tool
An automated database-guided analytical algorithm and software tool was
developed to classify individual leukemic cells from new patients in
different categories, based on sequential and/or simultaneous comparison
with cells from the AL patients in the database. Details about the algorithm
can be found in Supplementary Data and Supplementary Figures 4-10.
Brieﬂy cells were classiﬁed as follows (Figure 1):
1. Typical cells, related to single lineage cells (T, B, or Myeloid), were deﬁned
as events falling within the 2 s.d. of a single AL group and outside the 2
s.d. of the two other groups, when comparing the testing case to each
individual disease category independently in a PCA-guided analysis.
They were represented in the Compass software tool as a single-color
pointer directed to the appropriate disease category associated with the
percentage of the corresponding cells.
2. Mixed cells were deﬁned as cells that were not typical and fell outside
the 2 s.d. of the dominant group when challenging the case with





WHO diagnosis (n) T-ALL 46 145 191
BCP-ALL 158 377 535
AML 523b 134 657
MPAL 55 0 55
AUL 1 0 1
Gender (n) F 326 265 591
M 455 389 844
Unknown 2 2 4
Age (years) Median 39 6 10
Range 0-95 0-84 0-95
WBC (109/l) Median 19.8 14 16
Range 0.5-754 1–1000 0.5–1000
Disease phase (n) Diagnosis 767 634 1401
Relapse 12 21 33
Unknown 4 1 5
Sample type (n) Bone marrow 695 586 1280
Peripheral blood 87 68 155
Otherc 1 2 3
Abbreviations: AML, acute myeloid leukemia; AUL, acute undifferentiated
leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; MPAL,
mixed phenotype acute leukemia; T-ALL, T-cell acute lymphoblastic
leukemia. aadditional details can be found in Supplementary Table 1.
bIncluding two blastic plasmacytoid dendritic cell neoplasms cone
cerebrospinal ﬂuid sample in the validation cohort; two pleural efussion
samples in the database cohort.
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balanced supervised pairwise PCA-comparison of the two dominant
groups. These cells were represented in the Compass tool as a dual-
color arrow directed towards the mixed component associated with the
percentage of cells.
3. Transitional cells were deﬁned as virtually typical cells that fell within the
2 s.d. of the dominant group when challenging the case with balanced
unsupervised pairwise PCA-comparison of the two dominant groups.
These cells were represented in the Compass tool as a joint section
(sector) in between the typical (that is, T, B, Myeloid) and mixed (T/B, T/
M, B/M) components. By deﬁnition, transitional cells could not exist if no
mixed component was identiﬁed.
4. Other cells were also identiﬁed, namely, triphenotypic (T/B/M) cells
represented by a percentage in the middle of the Compass tool; and
immature cells, represented as a gray circle whose diameter was
proportional to the percentage of immature events. The classiﬁcation
system of these speciﬁc events is described in Supplementary Figures 2.
Finally, unclassiﬁed cells included events that did not fulﬁll any of the
criteria for any of the above described types of phenotype, and they
were not represented in the Compass tool.
This database-guided analysis was implemented as the Compass tool in
the Inﬁnicyt 2.0 software and it is now available worldwide.
Statistical analyses
The probability of selecting the wrong antibody panel and make the
wrong diagnosis by using only ALOT (expressed as p-values) and their
corresponding 95% conﬁdence intervals (95% CI), as well as the required
sample sizes for a p-value o0.05 or o0.08, were calculated based on the
number of cases evaluated and the actual mistakes made for all cases and
per individual WHO diagnostic subgroup using a proportional statistical
test (MATLAB software, Mathworks, Natick, MA, USA).
RESULTS
Building of the EuroFlow ALOT database
Data from 747 ALOT cases were used for the database (165 T-ALL,
422 BCP-ALL, 160 AML cases). These cases ﬁrst underwent a
quality check, by evaluating MFI values of multiple markers on
normal or malignant leukocytes. Cases with obviously atypical
expression (n= 81/747; 10.8%) due to technical errors/sample
quality issues, were excluded from further analysis
(Supplementary Figure 11 and Supplementary Table 2). The
resulting 666 cases were merged into a single .fcs ﬁle. Using APS
plots, with medians for each patient and SD curves for each
patient group shown, cases outside the 2 s.d. curves were checked
and excluded; this concerned 10 cases (1.5%). Therefore, the
resulting EuroFlow ALOT database consisted of 656 cases (145
T-ALL, 377 BCP-ALL, 134 AML) (Figure 2).
Figure 1. Schematic overview of the work process of the database-guided classiﬁcation of leukemic cells from individual patients during the
validation phase (Compass tool). The cells are classiﬁed as one of the indicated cell types based on the deﬁnitions in the second column, in
the order as shown from top to bottom. Examples are shown in the right column, in which the three reference groups are represented in blue
(T-ALL), green (BCP-ALL) and red (AML) (circles represent the mean of individual patients, the lines represent the 2 s.d. curves of the group),
and the cells from the case to be classiﬁed are represented by the individual gray and black events. The black events indicate the events that
fulﬁll the deﬁnition in the second column. Once a cell has been classiﬁed, it is removed from the subsequent steps. The different cell types are
visualized in a ﬁnal Compass, in which each cell type is represented in a speciﬁc manner (third column, see examples in Supplementary
Information).
Figure 2. Construction of the database and selection of cases.
Schematic overview of the construction of the database: initially 747
cases were evaluated. After a ﬁrst quality check 666 cases passed on
to the next stage. These 666 cases were merged in a single ﬁle; 10
cases which felt out of the 2 s.d. curves were excluded. The
remaining 656 cases entered the ﬁnal ALOT database.
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Contribution of markers in separating B, T and Myeloid
To evaluate the markers most contributing to the separation of
T-ALL, BCP-ALL and AML cells, the principal components of the
APS plot, with all three groups of patients, were analyzed
(Supplementary Figure 12). The ﬁrst principal component (x-axis)
showed major contribution of CD7 (24%), CD19 (24%) and CyCD3
(18%) and particularly separates T-ALL from BCP-ALL. The second
principal component (y axis) showed major contribution of CyMPO
(21%), FSC (17%), SSC (14%) and particularly separated AML from
BCP-ALL and T-ALL.
Database-guided classiﬁcation of AL patients
The resulting ALOT database and the newly developed database-
guided analysis tool were validated on 783 cases (47 T-ALL, 158
BCP-ALL, 522 AML; 1 AUL, 55 MPAL). All cases were analyzed using
the database-guided analysis tool and the results were compared
with the ﬁnal WHO2008 diagnosis, as established by the individual
centers. Based on the database-guided analysis, patients were
categorized as follows:
- Typical T, B or Myeloid (without mixed cells): the database-
guided analysis shows typical cells for only one lineage (either
T, B or Myeloid) and there are o1% mixed or
transitional cells.
- Typical T, B or Myeloid for only one lineage plus mixed cells:
the database-guided analysis shows410% typical cells (either
T, B or Myeloid), and 41% of mixed cells (T/M, T/B, M/B)
- Atypical: the database-guided analysis shows o10% of
typical cells (either T, B or Myeloid), irrespective of the
percentage of mixed cells.
- Mixed lineage: the database-guided analysis shows typical
cells in at least two lineages (either T+B, T+M, M+B, or T+B
+M), either with or without mixed or transitional cells.
The individual data for the cases in the various categories are
shown in Supplementary Table 4. Overall, the distribution of the
783 cases over these categories was 535 (68%), 170 (22%), 9 (1%)
and 69 (9%), respectively, and their distribution over the different
WHO categories is shown in Table 2. In 40/47 (85%) T-ALL, 153/158
(97%) BCP-ALL and 498/522 (95%) AML patients, the database-
guided analysis classiﬁed cells as typical T, B or Myeloid,
respectively. Furthermore, in 38/55 (69%) of MPAL-classiﬁed
patients the database-guided analysis showed typical cells in at
least two lineages (‘mixed lineage cases’) and in an additional
10/55 (18%) cases the database-guided analysis indicated either
large numbers of mixed cells (410%) or very low numbers of
typical cells (o10%), resulting in 87% of MPAL cases well
recognized.
Detailed evaluation of typical B, T or Myeloid cases (without mixed
cells)
Overall, 395/535 typical cases were classiﬁed as typical AML. The
average percentage of cells (± s.d.) deﬁned as typical Myeloid was
95.4 ± 9.1%. In only four cases the percentage of typical cells was
o50%, but always 410%. Review of these cases showed one
acute promyelocytic leukemia, one secondary AML, one t(8;21)-
positive AML and one AML case which weakly expressed CD19
and partially expressed CyMPO. Two cases classiﬁed as typical
AML by the database-guided analysis were originally diagnosed
with an MPAL (see Supplementary Table 8). Blinded local review
resulted in a diagnosis of AML with aberrant B-cell markers for
both cases.
In turn, 110/535 cases were classiﬁed as typical BCP-ALL. The
average percentage of cells (± s.d.) deﬁned as typical B was
96.6%±6.7%; in all cases the percentage was 450%. Two cases
were initially diagnosed as MPAL. Blinded local review resulted in
a diagnosis of BCP-ALL with aberrant weak CyMPO expression for
both cases (see Supplementary Table 8).
Finally, 30 cases were classiﬁed as typical T-ALL. The average
percentage of cells (± s.d.) deﬁned as typical T was 95.0%±9.9%; in
all cases the percentage was 450%. All cases were diagnosed as
T-ALL.
Detailed evaluation of Typical T, B or Myeloid with mixed cells
cases
In total, 170 cases (10 T-ALL 45 BCP-ALL, 105 AML and 10 MPAL)
were categorized as T, B or Myeloid with mixed populations, and
had ⩾ 10% of events deﬁned as typical T, B or Myeloid
(average ± s.d.: 71 ± 23% for T-ALL 67 ± 24% for BCP-ALL and
59± 27% for AML). By deﬁnition, all cases also had41% of mixed
cells; on average 9 ± 10% were within these mixed populations (T/
B: 16 ± 16%; T/M: 7 ± 7%; M/B: 10 ± 10%; TMB: 10 ± 13%). These
cases were further subdivided based on the percentage of cells in
the mixed population. Fifty-ﬁve cases had ⩾ 10% mixed cells and
of these 7 (13%) were diagnosed as MPAL. In contrast, only 3/115
(3%) cases with o10% mixed cells were diagnosed with an MPAL.
After blinded review of these three MPAL cases, one was
categorized as BCP-ALL with aberrant weak CyMPO+,14 whereas
the diagnosis of MPAL was maintained in the other two cases, due
to the presence of a major myeloid population and a small B-cell
population (see Supplementary Table 8). In the latter cases, the
Table 2. Results of the database-guided analysis per disease category
Compass result Disease category (initial diagnosis)a
T-ALL BCP-ALL AML MPAL AUL Total
Typical T, B, Myeloid 30 (64%) 108 (68%) 393 (75%) 4 (7%)b 0 (0%) 535
T, B or Myeloid with mixed populations o10% 9 (19%) 29 (19%) 75 (14%) 3 (5%)c 0 (0%) 116
T, B or Myeloid with mixed populations ⩾ 10% 1 (2%) 16 (10%) 30 (6%) 7 (13%) 0 (0%) 55
Atypical 4 (9%) 1 (1%) 1 (0%) 3 (5%) 0 (%) 9
Mixed lineage 3 (6%) 4 (3%) 23 (4%) 38 (69%) 1 (100%) 69
Total 47 158 522 55 1 783
Abbreviations: AML, acute myeloid leukemia; AUL, acute undifferentiated leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; MPAL, mixed
phenotype acute leukemia; T-ALL, T-cell acute lymphoblastic leukemia. aNumber of cases and percentages within each disease category. bAfter review: two
AML (with aberrant expression of B-cell markers) and two BCP-ALL with weak/doubtful CyMPO. cAfter review: one BCP-ALL with weak/doubtful CyMPO; one
case with a major myeloid population and a small MPAL (B/M) population (o10%), one case with a major myeloid population and a small BCP-ALL population
(o10%).
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two populations may better be analyzed separately in the
database-guided analysis.
Detailed evaluation of atypical cases
In seven cases the database-guided analysis deﬁned o10% of
cells as typical (either T, B or Myeloid). Three cases were diagnosed
as MPAL (see Supplementary Table 8). Case 4 showed typical
Myeloid cells and mixed T/M cells and was diagnosed with a
GATA1+ Down syndrome (DS)-AML. Case 5 was diagnosed with a
second relapse BCP-ALL but the database-guided analysis
suggested many mixed M/B cells; central review showed large
cells with a clearly deﬁned CD19+/CyCD79a+/CD34+/weak
CyMPO+ MPAL immunophenotype. Case 6 was diagnosed as
T-ALL; central and local review suggested an MPAL T/M (CyCD3
+/weak CyMPO+). Case 7 was diagnosed as T-cell malignancy with
a CD3+/CyCD3+/TCRgd+/CD34-/CD117-/CD1a-/CD10-/TdT-/CD4-/
CD8-/CD2+/CD5-/heterogeneous/CD7+/CD45+ immunopheno-
type: due to the absence of immature markers likely a mature
T-cell malignancy.
In two patients, the database-guided analysis did not show
typical cells at all. In one case the database-guided analysis
assigned most events as T/M cells (6%) and transitional T4T/M
cells (86%). Central review showed that the leukemic cells were
CD34+/weak CD45+/CyMPO-/CD19-/CyCD79a-/partially CD7+/par-
tially CyCD3+. Based on additional immunostainings, this case was
diagnosed as early-T-cell precursor (ETP) ALL. The second case was
CD34-/weak CD45+/CyCD3+/SmCD3-/strong CD7+/CD19-/
CyCD79a-/weak CyMPO+; all events were deﬁned unclassiﬁed by
the database-guided analysis. Further evaluations showed TdT-
positivity and a double NOTCH1 mutation; the case was diagnosed
as T-ALL.
Clearly, most of these cases were indeed atypical and required
special attention and subsequent staining of multiple classiﬁcation
panels.
Detailed evaluation of mixed lineage cases
In 69 cases, the database-guided analysis classiﬁed cells as typical
in two or more lineages, suggesting truly mixed-lineage pheno-
type AL. Indeed, in 38 cases (55%) diagnosis of MPAL was ﬁnally
made (see Figure 3 for an example). One case (1%) was diagnosed
as an AUL, the database-guided analysis indicated to typical
Myeloid and typical B cells in addition to mixed T/M, M/B, and TBM
cells and about one-third of transitional M4M/B cells. Of the
remaining 30 cases (43%; see Supplementary Table 8), most had
typical Myeloid and T cells; review of these cases frequently
showed a CyMPO-/CD7+ immunophenotype (AML with minimal
differentiation), generally also TdT was positive in these cases
(Figure 4). Other cases showed an atypical immunophenotype,
including one ETP-ALL, two blastic plasmacytoid dendritic cell
neoplasms, one t(9;22) and two MLL-positive cases. Finally, in a
few cases one of the populations deﬁned as typical seemed to be
due to non-purity of the gated blast cell population, resulting in
contamination with for example dendritic cells or normal B-cell
precursors. Such contaminations of the leukemic cell gate,
generally could well be identiﬁed by back-gating using the
database-guided analysis plots.
Algorithm for selection of appropriate classiﬁcation panels
We propose the algorithm shown in Figure 5 for selection of the
appropriate classiﬁcation panels. This algorithm directly guides
Figure 3. Example of a patient with an MPAL. The leukemic cells (in
red) are dim CD45+/CyCD3-/SmCD3-/partially CyMPO+/partially
CD34+/partially CD19+/partially CyCD79a+. The database-guided
analysis showed a main pointer to Myeloid (34%) and B (52%),
indeed suggesting an MPAL. The overall immunophenotype was
partially CD34+/partially CD117+/weak HLADR+/weak CD45+/CD13
+/CD33+/CD11b-/CD14-/CD15-/CD16-/CD36-/CD64-/CD56-/partially
TdT+/heterogeneous CD123+/CD66c+/CyIgM-/partially CD10
+/IgM-/partially CD22+/CD20-. Morphology showed 90% blasts,
Sudan black positive in 5% of cells. Cytogenetics showed 46,XX,t
(9;22)(q34;q11), BCR-ABL1-positive. According to WHO2008 the
patient was diagnosed as MPAL (myeloid/B) with t(9;22). Normal
T-cells (dark blue), NK cells (middle blue), mature B-cells (green),
eosinophils (light blue), granulocytes (purple), monocytes (orange)
and immature erythroid cells (brown) are shown as well.
Figure 4. Example of a patient with an AML with minimal
differentiation. The overall immunophenotype was CD34+/CD117
+/weak HLADR+/weak CD45+/CD13-/partially CD33+/CD11b-/
CD14-/ CD15-/CD16-/partially TdT+/CD36-/CD64-/CD56-/CD4-/het-
erogeneous CD123+/CD2-/CD5-. Morphology showed an AML, FAB-
M0. Cytogenetics were 46,XY, t(1;11)(q21;q23). According to
WHO2008 the patient was diagnosed as AML (with minimal
differentiation). Normal T-cells (dark blue), NK cells (middle blue),
mature B-cells (green), eosinophils (light blue), granulocytes
(purple), monocytes (orange) and immature erythroid cells (brown)
are shown as well.
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the user to the appropriate single classiﬁcation panel in 84 of
cases. In 16% of cases the database-guided analysis indicates that
there may be a mixed population and that the expert should
carefully evaluate the data and select the appropriate classiﬁcation
panel(s). Using this algorithm, in over 99% of cases the right
classiﬁcation panel(s) will be selected, in only two cases (0.3% of
all patients) the database-guided analysis directed towards an
AML panel whereas diagnosis of MPAL was made based on the
presence of a subset of cells that also expressed B-cell markers.
Based on the validation series results, the p-values for the total
cases and for each WHO diagnostic subgroup separately were:
total cases: 0.004 (95% CI: o0.001–0.009); AML: 0.004 (o0.001–
0.004); BCP-ALL: o0.001 (o0.001–o0.001); T-ALL: o0.001
(o0.001–o0.001); MPAL: o0.001 (o0.001–o0.001). Based on
the wrong decisions detected in the validation series the
estimated number of cases required for an error of o5%
(p-value o0.05) per WHO diagnostic subgroup would be lower
than 10.
Although the ALOT tube and database are not meant for
making a ﬁnal diagnosis but for guiding towards the appropriate
classiﬁcation panel, the database-guided analysis provided data
comparable to the ﬁnal WHO diagnosis already in493% of cases
(p= 0.046 (95%CI: 0.022–0.070; see Supplementary Information for
statistical details).
DISCUSSION
Flow cytometry is a frontline tool for orientation towards the right
diagnosis and the appropriate treatment protocol in AL. However,
no robust individual marker is sufﬁcient to correctly identify each
major disease category and consequently, interpretation requires
the integration of complex patterns of immunophenotypes. In
addition, the inherent biological variability of the disease makes
the overall picture even more complex, with overlapping (for
example, AML1-ETO AML co-expressing B-cell markers), inter-
mingled (for example, MPALs) or even unclassiﬁable (AUL)
immunophenotypes. Hence, it is recognized that immunopheno-
typing remains highly sensitive to technical procedures, including
expert-based identiﬁcation of the leukemic cells, and strongly
subjective and dependent on the expertise of laboratory
professionals for optimal interpretation of results. Within the
EuroFlow consortium, we previously reported the ALOT tube to
efﬁciently direct towards the appropriate classiﬁcation panel for
full characterization of AL. It included the major markers for
frontline screening of myeloid, B and T-cell lineages, and also for
detection of potentially more complex immunophenotypes, such
as MPALs and AULs. In this study, we built an ALOT database and a
PCA-based algorithm and software tool for further supporting
more objective and reproducible local selection of the appropriate
classiﬁcation panel(s).
Construction of the reference database required application of
standardized instrument settings, staining protocols and antibody
panels in all participating laboratories.7,8 Cases with clearly
atypical expression of certain markers were excluded from the
database; such atypical expression was most likely related to
technical problems or sample quality issues, although some
biological variability could not be ruled out in a few cases. The
relatively large number of excluded cases (12%) indicates that,
despite standardization, results are still not always comparable
and that stringent quality assurance programs per sample are
required.12 We aimed to build the reference database with typical
BCP-ALL, T-ALL and AML cases (656 cases in total). Thus, MPAL
cases were initially not included but temporarily stored aside and
ﬁnally evaluated in the validation cohort.
The ALOT tube and database are not meant for making a ﬁnal
diagnosis but for guiding towards the appropriate classiﬁcation
panel. Using the here-proposed algorithm, the right classiﬁcation
panel(s) will be selected in499% of cases. It should be noted that
the classiﬁcation panels also contain ‘cross-lineage’ markers
(CD19, CD22 and CD10 in AML panel, CD13, CD33 and CD117 in
BCP-ALL and T-ALL panels)7 that will facilitate right interpretation
of the ﬁnal data, even if only a single classiﬁcation panel is
originally selected. Nevertheless, given the composition of the
ALOT tube (including most lineage-deﬁning markers) the
database-guided tool already provides data comparable to the
ﬁnal WHO classiﬁcation in 493% of cases.
Prospective comparison of blast cells from individual AL cases
against the ALOT reference database using the ‘big data’ analytical
strategies here proposed, guides/helps the expert on the
interpretation of the overall immunophenotypic pattern of
leukemic cells in the diagnosis workup of hematological
malignancies. The advantage of the procedure is the capability
Figure 5. Proposed algorithm for application of the Compass tool results. Cases in which the Compass shows a main pointer towards B, T, or
Myeloid (with 410% of events) and that have no mixed events or o10% mixed events can be stained immediately with the classiﬁcation
panel of the main pointer. This accounts for 84% of cases (n= 650); of these only two (0,3%) were classiﬁed as MPAL after review. All other
cases (16% of total; n= 133) need manual selection of the right classiﬁcation panel; 36% of these were diagnosed as MPAL.
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of the algorithm to objectively analyze all single leukemic events
and to classify each of them individually. As such, it provides a
snapshot of the exact composition of the leukemic bulk by
describing all cellular subsets that reﬂect the intrinsic phenotypic
heterogeneity of AL. This single-cell analysis relies on accurate
simultaneous measurements of MFIs from eight different markers
plus two light scatter parameters. This is obviously more objective,
and in sharp contrast with the expert-based interpretation, which
takes into account an arbitrary categorical classiﬁcation of
negative versus positive and dim versus bright patterns of marker
expression for the dominant leukemic population,15 with no clear
insight into the phenotypic complexity of the total tumor load. As
a consequence, the algorithm is more likely to discern minor
immature cells or leaky phenotypes that are ignored by the
expert-based analysis. In that sense, the computer tools draw the
attention of the expert to possibly relevant subcomponents of the
leukemia, at the same time they fully allow for the parallel
conventional expert-based diagnostic interpretation. This may be
of particular relevance to prevent from missing MPALs because of
minor components, as found here for a few discrepant cases. In
line with this, one could hypothesize that these minor compo-
nents may be underestimated, possibly providing also a rationale
for switching-lineage leukemias.16 From a nosological perspective,
this further raises the question about the potential relevance of
the ability to dissect with precision the phenotypic composition of
the leukemic population. Thus, we provide here an objective tool
to decipher the phenotypic complexity of the leukemic population
that may meet clinical correlations, and raises the possibility to
revisit the criteria of the WHO classiﬁcation in the near future.
In this regard, the PCA-based algorithm applied to the three
typical AL groups of the reference database also highlighted the
relative contribution of each marker. Regarding the separation
between the three disease categories, CD7 had a major
contribution besides CD19 and CyCD3, and in fact CD7 was the
most contributing parameter. This may sound counter-intuitive at
ﬁrst glance given the fact that CD7 expression can also be seen in
AML. As a consequence, this approach could be used to further
improve the WHO classiﬁcation and one should consider including
the intensity of CD7 expression of individual leukemic cells within
a patient, in future classiﬁcation schemes for AL. As for the atypical
cases, notably MPALs and AULs, these are considered as more
difﬁcult diagnoses. Despite the criteria deﬁned by the WHO
classiﬁcation, the interpretation remains subjective, giving rise to
frequent ﬁle sharing between experts to consensually state the
diagnosis. This automated approach, once applied together with
standardized protocols and reagent panels, provides an innovative
and reproducible approach for robust delineation of these disease
categories. However, our strategy is extremely sensitive to the
quality of the selection criteria (that is, gates) used to identify the
leukemic cells, which might also beneﬁt from the automated
gating strategies recently developed by the EuroFlow
consortium.6 Thus, in the near future, databases with ALOT data
from normal subjects and patients may allow automated gating of
bone marrow and peripheral blood normal and leukemic cell
populations,6 thereby making the whole analyses even more
objective by avoiding contamination of the leukemic cells gates
with normal residual cellular events that may responsible for false
alarms of mixed lineage components.
In conclusion, here we show that building of large multicenter
databases of ﬂow cytometry immunophenotypic data is feasible, if
instrument settings, staining protocols and antibody panels are
well-standardized. The combination of such database with
database-guided analytical tools may support interpretation of
ﬂowcytometric data and guide the user towards appropriate
subsequent antibody panels. The ALOT database (656 AL patients)
and database-guided analytical tools were validated in 4780
patients and our results show that both typical and atypical
(mainly MPAL) cases could be recognized correctly in 499% of
cases. Thus, usage of the database-guided analysis may contribute
to more objective interpretation of immunophenotypic data and
improved diagnostics. This paves the way for improved database-
guided and computer-supported reproducible classiﬁcation of
single leukemic cells from individual patients, supervised by an
expert, also in other hematological malignancies and non-
hematological diseases.
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